27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Frequency Therapeutics Inc (NASDAQ:FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL).
- The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test.
- In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95% critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response.
- A single placebo patient had a 3.6 dB change.
- In the study, subjects did not show substantial changes in speech perception measures in quiet. The safety profile in the study was favorable, and no treatment-related serious adverse events were reported.
- BKB-SIN is a validated test designed for severe SNHL populations, measuring the change in signal-to-noise ratios required for a subject to correctly repeat words in a sentence.
- Related Link: Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors.
- Price Action: FREQ shares are up 3.00% at $5.68 during the market session on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!